第6笔成交价格为30.79元，成交10.00万股，成交金额307.90万元，溢价率为-10.00%，买方营业部为浙 商证券股份有限公司金华分公司，卖方营业部为中国中金财富证券有限公司北京建国门外大街证券营业 部。 第7笔成交价格为30.79元，成交7.00万股，成交金额215.53万元，溢价率为-10.00%，买方营业部为中信 建投证券股份有限公司北京望京证券营业部，卖方营业部为中国中金财富证券有限公司北京建国门外大 街证券营业部。 第8笔成交价格为30.79元，成交15.00万股，成交金额461.85万元，溢价率为-10.00%，买方营业部为国 泰海通证券股份有限公司昆明人民中路证券营业部，卖方营业部为中国中金财富证券有限公司北京建国 门外大街证券营业部。 12月26日，金凯生科收跌1.89%，收盘价为34.21元，发生10笔大宗交易，合计成交量87.2万股，成交金 额2684.89万元。 第9笔成交价格为30.79元，成交10.00万股，成交金额307.90万元，溢价率为-10.00%，买方营业部为广 发证券股份有限公司南京水佑岗证券营业部，卖方营业部为中国中金财富证券有限公司北京建国门外大 街证券营业部 ...

（编辑 丛可心 袁冠琳） 证券日报网讯 12月24日，金凯生科在互动平台回答投资者提问时表示，公司医药领域的产品主要为医 药中间体及原料药，严格规范的质量管理始终贯穿于产品研发、生产到交付的整个服务周期。公司国内 生产基地建立了ISO管理体系并持续获得认证通过，公司美国生产基地建立了cGMP体系并获得美国、 日本的药品监督管理机构现场检查通过。前述的质量体系建设是公司能够通过国际制药企业审厂并成为 其合格供应商的基础，也是公司产品质量能够符合标准的根本保证。 ...

Group 1 - The core viewpoint of the article indicates that the apparel and home textile sector experienced a decline of 0.88% compared to the previous trading day, with Taihu Snow leading the decline [1] - On the same day, the Shanghai Composite Index closed at 3917.36, reflecting an increase of 0.69%, while the Shenzhen Component Index closed at 13332.73, showing an increase of 1.47% [1] Group 2 - In terms of capital flow, the apparel and home textile sector saw a net outflow of 516 million yuan from main funds, while retail funds experienced a net inflow of 408 million yuan [2] - Additionally, speculative funds in the sector recorded a net inflow of 108 million yuan [2]

Market Overview - The Shanghai Composite Index is at 3885.23 points, above the annual line, with a change of 0.23% [1] - The total trading volume of A-shares is 1,404.985 billion yuan [1] Stocks Breaking Annual Line - A total of 196 A-shares have surpassed the annual line today [1] - Notable stocks with significant deviation rates include: - Debi Group (11.48%) - Lite-On Optoelectronics (10.24%) - Xinlong Health (7.36%) [1] Stock Performance Details - Top performers with deviation rates: - Debi Group: 19.99% increase, latest price 22.51 yuan, deviation rate 11.48% [1] - Lite-On Optoelectronics: 12.94% increase, latest price 25.49 yuan, deviation rate 10.24% [1] - Xinlong Health: 10.06% increase, latest price 7.77 yuan, deviation rate 7.36% [1] - Other notable stocks with smaller deviation rates include: - GQY Vision: 13.54% increase, latest price 7.38 yuan, deviation rate 6.37% [1] - Phoenix Shipping: 6.29% increase, latest price 5.07 yuan, deviation rate 5.66% [1] Additional Stock Insights - Stocks with lower deviation rates that just crossed the annual line include: - Hanxin Technology: 7.99% increase, latest price 42.70 yuan, deviation rate 3.99% [1] - Jinjiang Online: 4.81% increase, latest price 15.92 yuan, deviation rate 3.89% [1] - The overall market shows a mix of strong performers and those just reaching the annual line, indicating varied investor sentiment [1][2]

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and limited raw materials for new drug development projects for globally recognized pharmaceutical companies [2][8]. - The company has a significant focus on fluorinated CDMO services, including specialized fluorination agents and other fluorinated products [3][8]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to the parent company of 103 million yuan, reflecting a substantial increase of 163.24% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On December 16, the company's stock price fell by 2.50%, with a trading volume of 39.89 million yuan and a turnover rate of 2.15%, resulting in a total market capitalization of 3.896 billion yuan [1]. - The stock has shown no clear trend in major capital inflows, with a net outflow of 4.2829 million yuan today, ranking 27th out of 52 in its industry [5][6].

证券日报网讯 12月15日，金凯生科在互动平台回答投资者提问时表示，截至2025年12月10日，公司股 东数为14355户。 （文章来源：证券日报） ...

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and limited raw materials for new drug development projects for well-known pharmaceutical companies globally [2][8]. - The company has a significant focus on fluorinated CDMO services, including specialized fluorination agents and other fluorinated products [3]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, with a remarkable year-on-year increase of 163.24% [8]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Group 3: Market Activity - On December 15, the company's stock price decreased by 0.54%, with a trading volume of 30.35 million yuan and a turnover rate of 1.61%, resulting in a total market capitalization of 3.996 billion yuan [1]. - The stock has seen a net inflow of 861,200 yuan from major investors today, with a ranking of 10 out of 52 in its industry, indicating a slight increase in major investor positions over the past two days [5][6].

证券日报网讯 12月10日晚间，太湖雪发布公告称，截至本公告披露日，公司在中信银行股份有限公司 吴江盛泽支行开设的募集资金专户和在苏州银行股份有限公司吴江支行开设的募集资金专户，募集资金 均已全部使用完毕，并完成对应账户的注销手续，公司与保荐机构东吴证券股份有限公司、开户银行签 署的相关《募集资金专户三方监管协议》相应终止。 （文章来源：证券日报） ...

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and limited raw materials for new drug development projects for globally recognized pharmaceutical companies [2][8]. - The company has a significant focus on fluorinated CDMO services, including special fluorinated agents and various fluorination processes [3]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the Renminbi [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved operating revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, with a year-on-year increase of 163.24% [8]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Group 3: Market Activity - On December 10, the company's stock price decreased by 1.01%, with a trading volume of 33.1865 million yuan and a turnover rate of 1.75%, resulting in a total market capitalization of 4.019 billion yuan [1]. - The stock has shown no significant trend in major capital inflows, with a net outflow of 2.4753 million yuan today, indicating a lack of clear control by major investors [5][6].

Group 1 - The core theme of the event is the integration of digital technology in the cultural sector, aiming to establish a high-level dialogue and cooperation platform between Chengdu and the Yangtze River Delta region [1] - The event attracted over a hundred participants from key cultural enterprises and investment institutions, leading to the establishment of the "Chengdu-Yangtze River Delta Cultural Industry Innovation Development Alliance" [1][4] - Chengdu's digital cultural industry achieved a revenue of 325.61 billion yuan, with a year-on-year growth of 9.5%, and a value-added of 113.58 billion yuan, growing by 10.5% [9] Group 2 - The Chengdu delegation visited key cultural enterprises in Suzhou, gaining insights into the integration of culture and technology, and traditional craftsmanship with modern industry [4] - The event featured the launch of over a hundred investment opportunities and supply-demand lists in various fields, including film and animation, digital music, and cultural tourism [4] - Chengdu's cultural enterprises, including state-owned groups, presented their strategic layouts and cooperation needs in content production and cultural tourism integration [5] Group 3 - Chengdu's key cultural parks, such as the Dongjiao Memory Art District and Chengdu Film City, showcased their successful transformation and development strategies [6] - The establishment of the Chengdu Sci-Fi and Future Industry Development Fund, with a target scale of 3.3 billion yuan, aims to support the high-quality development of the digital cultural industry [8] - The event served as a platform for Chengdu to learn from the advanced experiences of the Yangtze River Delta region in digital technology and capital aggregation [9] Group 4 - Multiple projects were signed during the event, including the Red Warehouse 101 Tianfu Design Industry Park Phase II project, which aims to attract technology and digital media industries [16] - The Chengdu-Yangtze River Delta Cultural Industry Innovation Development Alliance will facilitate cross-regional cooperation and resource sharing among cultural enterprises [18] - The event is part of Chengdu's strategy to engage with the Yangtze River Delta, enhancing its cultural industry through collaboration and knowledge exchange [21]